Brensocatib

Chemical formula: C₂₃H₂₄N₄O₄  Molecular mass: 420.18 g/mol  PubChem compound: 118253852

Active ingredient description

Brensocatib is a competitive, reversible inhibitor of dipeptidyl peptidase 1 (DPP1). DPP1 activates pro-inflammatory neutrophil serine proteases (NSPs) during neutrophil maturation in the bone marrow. Activated NSPs are implicated in the pathogenesis of neutrophil-mediated NCFB inflammation. In cell-based assays, DPP1 inhibition by brensocatib reduces the activity of NSPs including neutrophil elastase, cathepsin G, and proteinase 3.

Product monographs

Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):

Document Type Information Source  
 BRINSUPRI Tablet MPI, US: SPL/PLR FDA, National Drug Code (US)

Structural formula

Graphic representation of the active ingredient's molecular structure

External identifiers

DrugBank Drug: DB15638
KEGG Drug: D12120
PubChem Compound: 118253852
UNII Identifier: 25CG88L0BB
BRENSOCATIB

Medicines

Brensocatib is an active ingredient of these brands:

United States (US)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.

 
Next: Usage >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈